Want to see IRD full AI Analyst Report?
Top Page
Opus Genetics
(NASDAQ:IRD)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.50
▲(13.64% Upside)
Action:Reiterated
Date:08/07/26
IRD scores below average primarily due to very weak financial performance (large losses, negative equity with added debt, and accelerating cash burn), which outweighs the more constructive pipeline-related corporate updates. Technicals are mixed/neutral and valuation is constrained by negative earnings and no indicated dividend support.
Positive Factors
Diversified clinical pipeline
A portfolio of five advancing gene‑therapy programs spreads development risk across multiple IRD indications, increases chances of successful readouts across 2027, and leverages rare-disease incentives and partnerships to create multiple durable value inflection points beyond any single trial outcome.
Negative Factors
Material balance sheet deterioration
Negative equity combined with newly incurred debt represents a structural weakening of financial flexibility, raising refinancing and covenant risks. Over months, this constrains strategic options, increases cost of capital, and heightens the likelihood of dilutive financing if clinical progress stalls or expenses exceed forecasts.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified clinical pipeline
A portfolio of five advancing gene‑therapy programs spreads development risk across multiple IRD indications, increases chances of successful readouts across 2027, and leverages rare-disease incentives and partnerships to create multiple durable value inflection points beyond any single trial outcome.
Read all positive factors
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$303.66M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth-36.09%
EPS Growth24.84%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding83,195,820
10 Day Avg. Volume943,049
30 Day Avg. Volume1,081,647
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$13.47M
Opus Genetics Business Overview & Revenue Model
Company Description
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refr...
How the Company Makes Money
null...
Opus Genetics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.86M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 9.84M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -104.92M | -48.07M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -107.61M | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | ||||||
| Total Assets | 92.97M | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 88.81M | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 34.93M | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 105.95M | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | -12.99M | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | ||||||
| Free Cash Flow | -40.67M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -40.67M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 97.15M | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Positive
3.08
Price Trends
3.74
Negative
4.30
Negative
3.56
Positive
Market Momentum
<0.01
Negative
50.82
Neutral
26.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Positive. The current price of 3.08 is below the 20-day moving average (MA) of 3.57, below the 50-day MA of 3.74, and below the 200-day MA of 3.56, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.82 is Neutral, neither overbought nor oversold. The STOCH value of 26.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRD.
Opus Genetics Risk Analysis
Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opus Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $333.49M | -5.03 | -42.80% | ― | ― | 59.89% | |
56 Neutral | $741.68M | -14.49 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $564.41M | -8.03 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $303.66M | -2.87 | 1147.63% | ― | -36.09% | 24.84% | |
44 Neutral | $97.85M | -2.72 | -171.19% | ― | ― | 83.55% | |
42 Neutral | $279.50M | -0.58 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
IRD
Opus Genetics
3.69
2.58
232.43%
OVID
Ovid Therapeutics
2.84
1.90
202.13%
STTK
Shattuck Labs
7.45
6.42
623.30%
IKT
Inhibikase Therapeutics
2.40
0.70
41.18%
SRZN
Surrozen
24.00
12.85
115.25%
BMEA
Biomea Fusion
1.35
-0.37
-21.51%
Opus Genetics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Opus Genetics Showcases Expanding Gene Therapy Pipeline Progress
Positive
Jun 16, 2026
On June 16, 2026, Opus Genetics hosted an RD Science Forum to showcase five gene therapy programs for inherited retinal diseases, highlighting three new candidates moving toward the clinic and promising early data from ongoing LCA5 and BEST1 trial...
Business Operations and Strategy
Opus Genetics Highlights Advancing Inherited Retinal Disease Pipeline
Positive
Jun 16, 2026
On June 16, 2026, Opus Genetics hosted a virtual RD Science Forum at which management and external key opinion leaders presented an overview of the company’s clinical pipeline in inherited retinal diseases. The event, available by webcast, h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.